Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue

    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20200056

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • ECOG EA6141 - Feun, Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:
    RCemailImg Milton Ortega Uribe
    RCphone +1 (305) 2432086

    IRB: 20150909

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: ECOG

    Enrolling Sites:

    Deerfield
    Plantation
    Sylvester

    Title:

    Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

    Eligibility Criteria - NCT02339571 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191308 - Feun Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:
    RCemailImg Silvia Garcia
    RCphone +1 (305) 2433009

    IRB: 20191308

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: INXMED

    Enrolling Sites:

    Sylvester

    Title:

    A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects with Metastatic Melanoma

    Eligibility Criteria - NCT04109456 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201288 - Feun Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:

    IRB: 20201288

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: ECOG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    EA6192 A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)

    Eligibility Criteria - NCT04462406 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210377 - Feun Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:
    RCemailImg Ryan Barrios
    RCphone +1 (305) 9515919

    IRB: 20210377

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: BioNTech SE

    Enrolling Sites:

    Sylvester

    Title:

    Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD1-/PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma

    Eligibility Criteria - NCT04526899 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210173 - Hernandez Aya Leonel

  • Investigator:
    Leonel Hernandez Aya
    RCname Email

    Coordinator:
    RCemailImg Ryan Barrios
    RCphone +1 (305) 9515919

    IRB: 20210173

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Eye and Orbit

    Sponsor: Foghorn Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects with Metastatic Uveal Melanoma

    Eligibility Criteria - NCT04879017 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220081 - Hernandez Aya Leonel

  • Investigator:
    Leonel Hernandez Aya
    RCname Email

    Coordinator:
    RCemailImg Ryan Barrios
    RCphone +1 (305) 9515919

    IRB: 20220081

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: BRISTOL-MYERS SQUIBB

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

    Eligibility Criteria - NCT05002569 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191171 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:
    RCemailImg Edda Bisbal-Loubriel

    IRB: 20191171

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Other Skin

    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester

    Title:

    A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

    Eligibility Criteria - NCT04050436 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200237 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:
    RCemailImg Edda Bisbal-Loubriel

    IRB: 20200237

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: VYRIAD

    Enrolling Sites:

    Sylvester

    Title:

    Phase 2 Trial of Voyager V1 (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination with Cemiplimab in patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma

    Eligibility Criteria - NCT04291105 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200847 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:
    RCemailImg Milton Ortega Uribe
    RCphone +1 (305) 2432086

    IRB: 20200847

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Eye and Orbit

    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Sylvester

    Title:

    A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients with Metastatic Uveal Melanoma

    Eligibility Criteria - NCT04552223 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201379 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:
    RCemailImg Christina Estevez
    RCphone +1 (305) 2438376

    IRB: 20201379

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: ECOG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma

    Eligibility Criteria - NCT04527549 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201381 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:
    RCemailImg Edda Bisbal-Loubriel

    IRB: 20201381

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: SWOG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

    Eligibility Criteria - NCT04511013 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210034 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:

    IRB: 20210034

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Esophagus,Lung,Melanoma, skin,Ovary,Prostate,Unknown Sites

    Sponsor: Dragonfly Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

    Eligibility Criteria - NCT04423029 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210617 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:
    RCemailImg Ryan Barrios
    RCphone +1 (305) 9515919

    IRB: 20210617

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: DOT Therapeutics-1 Inc. (Day One)

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 2, Subprotocol of DAY101 Monotherapy for Patients with Recurrent, Progressive, or Refractory Solid Tumors with MAPK Pathway Aberrations

    Eligibility Criteria - NCT04985604 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210978 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:
    RCemailImg Edda Bisbal-Loubriel

    IRB: 20210978

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: Instil Bio

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)

    Eligibility Criteria - NCT05050006 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220021 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:
    RCemailImg Milton Ortega Uribe
    RCphone +1 (305) 2432086

    IRB: 20220021

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: Agenus

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Sylvester

    Title:

    A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients with Advanced Cancer

    Eligibility Criteria - NCT04121676 *This information has been extracted from " www.clinicaltrials.gov"

  • RTX-240-01 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200686

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Multiple

    Sponsor: Rubius Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB

    Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211216 - Moller Mecker

  • Investigator:
    Mecker Moller
    RCname Email

    Coordinator:
    RCemailImg Edda Bisbal-Loubriel

    IRB: 20211216

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: ECOG

    Enrolling Sites:

    Sylvester

    Title:

    Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination With CMP-001 in Patients With Operable Melanoma: Efficacy and Biomarker Study

    Eligibility Criteria - NCT04708418 *This information has been extracted from " www.clinicaltrials.gov"

  • Tbio-6517-ITu-001 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20200277

    SDG: Colorectal Cancer
    Disease Site(s):

    Multiple

    Sponsor: TSB

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Rodriguez, Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Breast-Female,Colon,Melanoma, skin

    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester

    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201298 - Tang Jennifer

  • Investigator:
    Jennifer Tang
    RCname Email

    Coordinator:
    RCemailImg Milton Ortega Uribe
    RCphone +1 (305) 2432086

    IRB: 20201298

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: ETCTN

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

    Eligibility Criteria - NCT02978625 *This information has been extracted from " www.clinicaltrials.gov"

  • ATRC-101-A01 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20200938

    SDG: Other
    Disease Site(s):

    Breast,Colon,Lung,Melanoma, skin,Ovary

    Sponsor: Atreca Inc

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination with Other Anticancer Agents in Adults with Advanced Solid Malignancies

    Eligibility Criteria - NCT04244552 *This information has been extracted from " www.clinicaltrials.gov"